Haleon plc engages in the research and development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides therapeutic oral health, pain relief, respiratory health, digestive health, and other products, as well as vitamins, minerals, and supplements. Its portfolio of brands include Panadol, Voltaren, Advil, Otrivin, Theraflu, Sensodyne, Polident, parodontax, and Centrum. The company was formerly known as DRVW 2022 plc and changed its name to Haleon plc in February 2022. Haleon plc was incorporated in 2021 and is headquartered in Brentford, the United Kingdom.

Haleon plc

Haleon is a consumer health company that focuses on delivering better everyday health with humanity. The company claims to be well positioned to help individuals through its strong portfolio of brands built on science and human understanding.

Haleon

Pharmaceutical Manufacturing

Haleon HealthPartner (HCP)

Manufacturing

Voltarol GB

Consumer Services

Haleon Re/Wire Health Studio

Haleon | 240,656 followers on LinkedIn. Better everyday health with humanity 💚 | You have loved and trusted our brands for over 170 years. We have a clear purpose, to deliver better everyday health with humanity. 💚
Our category-leading brands include Sensodyne, Panadol, Centrum, TUMS, Advil, Otrivin and Voltaren. We combine deep human understanding and trusted science to make everyday health more inclusive, more achievable and more sustainable.

Andrew Gould

Agnes Adusz

Head of HR EMEA and LATAM at Haleon

Jooyong Lee

VP & General Manager Great Britain and Ireland

Bas Vorsteveld

The World Health Organization (WHO) has identified climate change as a fundamental threat to human health, with 3.6 billion people already living in areas highly susceptible to climate change. In addition to the steps we are taking to be a more sustainable business, we are also actively involved in initiatives that help consumers better understand the impacts of climate change on their everyday health. Learn more about some of the ways we are doing this here: https://lnkd.in/dX8yar2i #ClimateChangesHealth #Haleon

Our CEO Brian McNamara returned to CNBC 's Mad Money show this week with Jim Cramer . They spoke about the real momentum in the business and the exciting opportunity ahead for #Haleon .

Happy Diwali to all those celebrating. #Diwali #Haleon

We’re delighted to welcome Dawn Allen as Haleon’s new Chief Financial Officer. Dawn joins us from Tate & Lyle plc where she was CFO and member of the Executive Team and Board. Prior to this, Dawn spent 25 years at Mars Inc. where she was more recently Global CFO and Vice President of Global Transformation. Welcome to Haleon, Dawn! Learn more here: https://lnkd.in/dpTBHKdh

Haleon’s Health Inclusivity Screener is a new AI powered tool which can help address the inclusivity gap. It’s the only data driven tool of its kind to analyse digital advertising content for both readability and inclusivity metrics. These insights will help Haleon to deliver digital content which is accessible, easy to understand, and which reflects the millions of consumers we serve globally. 83% of global advertisements fail to meet basic accessibility standards, while 54% of consumers saying they don’t feel culturally represented in online advertising. We’re committed to taking action to help close the health inclusivity gap. That includes addressing health literacy, accessibility and representation within healthcare advertising. Learn more about how our Panadol brand has used the tool here: https://lnkd.in/dKAtVY9z

As part of its Actions to Breathe Cleaner initiative, Otrivine has partnered with England Athletics to develop Clean Air Guidance aimed at reducing runners’ exposure to air pollution. The recent, long-standing Potters ‘Arf Marathon in Stoke-on-Trent, UK, was the first race in the UK to adopt this guidance, supporting runners’ health and raising awareness about air pollution. #CleanAirRace #Otrivine #ActionstoBreatheCleaner

At Haleon, we remain committed to promoting inclusive health systems. Last week, our Chief Marketing Officer Tamara Rogers , took part in a panel discussion on the subject alongside the World Health Summit held in Berlin, Germany. We joined forces with the independent policy institute Chatham House , to discuss how to foster trust and resilience in the health sector amidst a fractured geopolitical environment. The panel concluded that if countries and the public and private sectors work together to foster a more inclusive approach to health, the effects could be transformative in achieving global health and equity targets. A huge thanks to Emma Ross , Helen Clark , Monique Vledder and Judy Stenmark for being part of this important conversation. #WorldHealthSummit #HealthInclusivity #Haleon

Meet some of the people whose dedication and expertise helped make Sensodyne Clinical White toothpaste a trusted choice for sensitive teeth and whitening. Hear the incredible story of the product from the perspectives of Franck, Emma, Nadeen and Charlie who have all worked on bringing this innovation to our shelves. Charlie Parkinson, Global Medical Affairs Director for Sensodyne at Haleon says "Seeing the product on the shelf, we are very proud but equally it reminds you of the team you were part of.” #Haleon #Sensodyne #ClinicalWhite #Podcast #OralHealth #Innovation

Can you have whiter teeth while managing sensitivity at the same time? In the second episode in our podcast series Happy Healthy Humans by Haleon, we’re talking about Sensodyne’s new product Clinical White. This episode features an insightful conversation with Charlie Parkinson, Global Medical Affairs Director for Sensodyne at Haleon and we discuss teeth whitening. Learn about the journey of this remarkable product from concept to market. Tune in now on Spotify and Apple podcasts. Spotify: https://lnkd.in/eWfbA7DC Apple podcasts: https://lnkd.in/ebJ9wvKU #Haleon #Sensodyne #ClinicalWhite #Podcast #OralHealth #Innovation

Osteoarthritis is a leading cause of disability, impacting quality of life for 595 million people globally. We want to play a leading role in developing better health outcomes for those affected, so we’ve teamed up with the University of Sydney to launch a five-year research fellowship. This programme will investigate the therapeutic role of supplements in managing osteoarthritis symptoms and digital technologies that improve mobility. As a global leader in pain relief and vitamins, minerals and supplements – through brands like Panadol, Voltaren, Centrum and Caltrate – we’re collaborating and driving innovation to find new and better ways of managing this chronic condition. #haleon #innovation

	Dec '19	Dec '20	Dec '21	Dec '22	Dec '23
net income	687M -	1.18B 71.91%	1.44B 21.85%	1.12B 22.24%	1.11B 0.71%
depreciation and amortization	260M -	305M 17.31%	268M 12.13%	287M 7.09%	309M 7.67%
deferred income tax	199M -	410M 106.03%	197M 51.95%	62M 68.53%	354M 470.97%
stock based compensation	-261M -	-702M 168.97%	-376M 46.44%	-62M 83.51%	76M 222.58%
change in working capital	-461M -	15M 103.25%	-152M 1,113.33%	181M 219.08%	-107M 159.12%
accounts receivables	-57M -	18M 131.58%	14M 22.22%	-85M 707.14%	38M 144.71%
inventory	232M -	130M 43.97%	-17M 113.08%	-292M 1,617.65%	-131M 55.14%
accounts payables	-256M -	140M 154.69%	41M 70.71%	387M 843.90%	112M 71.06%
other working capital	-380M -	-273M 28.16%	-190M 30.40%	171M 190%	-126M 173.68%
other non cash items	362M -	198M 45.30%	-20M 110.10%	476M 2,480%	357M 25%
net cash provided by operating activities	786M -	1.41B 79.01%	1.36B 3.62%	2.06B 52.14%	2.10B 1.79%
investments in property plant and equipment	-243M -	-318M 30.86%	-298M 6.29%	-328M 10.07%	-336M 2.44%
acquisitions net	120M -	241M 100.83%	112M 53.53%	9.21B 8,124.11%	-71M 100.77%
purchases of investments	53M -	96M 81.13%	-112M 216.67%	-9.21B 8,124.11%
sales maturities of investments	219M -	158M 27.85%	100M 36.71%	700M 600%
other investing activites	142M -	853M 500.70%	165M 80.66%	-9.16B 5,649.09%	273M 102.98%
net cash used for investing activites	291M -	1.03B 253.95%	-33M 103.20%	-8.78B 26,518.18%	-134M 98.47%
debt repayment	-1M -	-10M 900%	-8M 20%	-1.52B 18,875%	-553M 63.57%
common stock issued					38M -
common stock repurchased					-38M -
dividends paid	-1.15B -	-2.37B 105.82%	-1.15B 51.58%	-2.68B 133.62%	-388M 85.53%
other financing activites	228M -	-56M 124.56%	-80M 42.86%	11.11B 13,988.75%	-627M 105.64%
net cash used provided by financing activities	-925M -	-2.44B 163.46%	-1.24B 49.28%	6.91B 659.14%	-1.57B 122.69%
effect of forex changes on cash	-14M -	-6M 57.14%	-5M 16.67%	15M 400%	-15M 200%
net change in cash	138M -	-6M 104.35%	82M 1,466.67%	205M 150%	383M 86.83%
cash at beginning of period	191M -	329M 72.25%	323M 1.82%	406M 25.70%	611M 50.49%
cash at end of period	329M -	323M 1.82%	405M 25.39%	611M 50.86%	994M 62.68%
operating cash flow	786M -	1.41B 79.01%	1.36B 3.62%	2.06B 52.14%	2.10B 1.79%
capital expenditure	-243M -	-318M 30.86%	-298M 6.29%	-328M 10.07%	-336M 2.44%
free cash flow	543M -	1.09B 100.55%	1.06B 2.85%	1.74B 63.99%	1.76B 1.67%

COM:HALEON

Haleon

Last Close

372.40

22/11 16:52

Market Cap

305.73M

Beta: -

Volume Today

12.08M

Avg: -

Preview